AXSOME THERAPEUT. DL-0001 WKN: A2AA7B ISIN: US05464T1043 Kürzel: AXSM Forum: Aktien Thema: Hauptdiskussion

Schön, dass zumindest nichts negatives aus der FDA Richtung kam. Wäre fair wenn diese diesmal rechtzeitig ankündigt, ob sie das pdufa für axs07 halten können. Zwei Zulassung wären natürlich super toll für Axsome

Hat jemand den conference call angehört? Habe ihn leider verpasst.

Gucke

Ziiieehh.... ✌️✌️

Axsome Therapeutics GAAP EPS of -$0.90 beats by $0.08 https://seekingalpha.com/news/3807524-axsome-therapeutics-gaap-eps-of--090-beats-by-008 Axsome Therapeutics press release (NASDAQ:AXSM): Q4 GAAP EPS of -$0.90 beats by $0.08. At December 31, 2021, Axsome had $86.5M of cash compared to $183.9 million at December 31, 2020. Axsome believes that its current cash, along with the remaining committed capital from the $300M term loan facility, is sufficient to fund anticipated operations, based on the current operating plan, which includes costs for the potential commercial launch of AXS-05 in MDD and AXS-07 in migraine, into 2024. Axsome expects that its operating expenses will increase year over year as it continues to build out the commercial function and further advance its pipeline.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update https://www.globenewswire.com/news-release/2022/03/01/2394104/33090/en/Axsome-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Business-Update.html

Gefühlt nur noch bis zum 01.03 😁 zumindest in meiner Welt

Bergab aber es Läuft. Wie lange dauert überhaupt diese AXS-05 Zulassung ,Gefühlte 3 Jahre???

Läuft

Ist ruhiger geworden....Adler.... ....in der Ruhe liegt die Kraft!

✌️

Weiter Richtung 45 Dollar.... erstmal!

https://www.investorsobserver.com/news/stock-update/will-axsome-therapeutics-inc-axsm-stay-at-the-top-of-the-healthcare-sector

https://m.aktiencheck.de/news/Artikel-Axsome_Therapeutics_Aktie_So_kann_es_nicht_weitergehen-14085869

rolling stones

FDA to perform Axsome facility inspection prior to AXS-07 action date https://seekingalpha.com/news/3796953-fda-to-perform-axsome-facility-inspection-prior-to-axs-07-action-date-shares-rise-3 Axsome Therapeutics (NASDAQ:AXSM) said that it was informed by the FDA that it should be able to perform a required inspection of a contract manufacturing facility prior to the PDUFA date of April 30, 2022 for AXS-07. ... The FDA had previously told the company that due to COVID-19-related travel restrictions it might not be able to conduct the inspection prior to the April action date. The AXS-07 NDA for migraine is backed by two late-stage trials.